Carter Worth And Mike Khouw's Amgen Trade

On
CNBC's Options Action
, Carter Worth analyzed
Amgen, Inc.AMGN
from a technical standpoint.

He said that the stock consistently outperformed iShares NASDAQ Biotechnology Index (ETF) IBB, which is in his opinion a basis for a bullish setup. Worth believes the stock is going to break out on the upside and reach its highs at $181.

Related Link: Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences

Mike Khouw thinks the best way to make a bullish bet is by selling the October 165 put for $6.70. The trades starts to lose money below $158.30 or 4.45 percent lower from the current stock price. If Amgen stays above $165 at the October expiration, Khouw is going to collect 4 percent in three months.

Full ratings data available on Benzinga Pro.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com with the story link to let us know!

Date of Trade
ticker
Put/Call
Strike Price
DTE
Sentiment
Posted In: BiotechCNBCLong IdeasHealth CareTechnicalsOptionsMarketsMediaTrading IdeasGeneralCarter WorthMike KhouwOptions Action
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...